Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 797-805

  Güthlein, Frank ^a   Burger, Angelika M ^a   Brandl, Martin ^a   Fiebig, Heinz Herbert ^a   Schubert, Rolf ^a   Unger, Clemens ^a   Massing, Ulrich ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Drug delivery systems; Drug targeting; Liposomes; Pharmacokinetics; Phospholipids; Tissue distribution; Toxicity; Vincristine; Xenograft model antitumor assay

Indexed keywords

ANTINEOPLASTIC AGENT; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; FEMALE; GEL; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR; VESICULAR PHOSPHOLIPID GEL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; GELS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; NEOPLASMS, EXPERIMENTAL; PHOSPHOLIPIDS; SOLUBILITY; TISSUE DISTRIBUTION; VINCRISTINE;

EID: 0036746942     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00003     Document Type: Article

References (37)

1. Beck WT, Cass CE, Houghton PJ. Anticancer drugs from plants: vinca alkaloids and taxanes. In: Holland F, ed. Cancer medicine. Hamilton, Ontario: Decker 1997
2. Bensch KG, Malawista SE. Microtubule crystals: a new biophysical phenomenon induced by Vinca alkaloids. Nature 1968; 218: 1176-7
3. DeVita VT, Hellmann S, Rosenberg S. Cancer: principles & practice of oncolgy. Philadelphia, PA: Lippincott-Raven 1997
4. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992; 44: 1-16; discussion 66-19
5. Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73: 2515-9
6. Jackson Jr DV, Sethi VS, Spurr CL, et al. Intravenous vincristine infusion: phase I trial. Cancer 1981; 48: 2559-64
7. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1993; 33: 17-24
8. Brandl M. Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev 2001; 7: 59-85
9. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 2000; 3: 171-7
10. Boman N, Bally MB, Cullis PR, Mayer LD, Webb MS. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J Liposome Res 1995; 5: 523-41
11. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62: 199-204
12. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54: 2830-3
13. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990; 50: 575-9
14. Mayer LD, St-Onge G. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 1995; 232: 149-57
15. Millar JL, Millar BC, Powles RL, et al. Liposomal vincristine for the treatment of human acute lymphoblastic leukaemia in severe combined immunodeficient (SCID) mice. Br J Haematol 1998; 102: 718-21
16. Tokudome Y, Oku N, Doi K, Namba Y, Okada S. Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta 1996; 1279: 70-4
17. Vaage J, Donovan D, Mayhew E, Uster P, Woodle M. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 1993; 54: 959-64
18. Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 1998; 42: 461-70
19. Zhu G, Oto E, Vaage J, et al. The effect of vincristine-polyanion complexes in stealth liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 1996; 39: 138-42
20. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697-705
21. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000; 11: 69-72
22. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993; 1152: 253-8
23. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896-904
24. Kirby C, Gregoriadis G. The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 1983; 32: 609-15
25. Brandl M, Massing U. Vesicular phospholipid gels. In: Weissig V, Torchillin V, eds. Liposomes: practical approaches. Oxford: IRL Press at Oxford University Press 2002: in press
26. Brandl M, Drechsler M, Bachmann D, Bauer KH. Morphology of semisolid aquous phosphatidylcholine dispersions, a freeze fracture electron microscopy study. Chem Phys Lipids 1997; 87: 65-72
27. Brandl M, Drechsler M, Bachmann D, Tardi C, Schmidgen M, Bauer KH. Preparation and characterization of semisolid phospholipid dispersions and dilutions thereof. Int J Pharm 1998; 170: 187-99
28. Moog R, Burger AM, Brandl M, et al. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol 2002; 49: 356-66
29. Tardi C, Drechsler M, Bauer KH, Brandl M. Steam sterilization of vesicular phospholipid gels. Int J Pharm 2001; 217: 161-72
30. van Tellingen O, Beijnen JH, Nooyen WJ. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. J Pharm Biomed Anal 1991; 9: 1077-81
31. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988; 22: 195-201
32. Geran RI, Greenberg NH, Macdonald MM, Abbott BJ. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR#D program, DCT, NCI. Natl Cancer Inst Monogr 1977; 151-3
33. Ovejaera AA. The use of human tumor xenografts. In: Kallmann RF, ed. Rodent tumor models in experimental cancer chemotherapy. Oxford: Pergamon 1987: 218-20
34. Fiebig HH, Berger PD, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts. In: Fiebig HH, Berger PD, eds. Immunodeficient mice in oncology. Basel: Karger 1992: 321-51
35. Uster P. Therapeutic application of vincristine in conventional and sterically stabilized liposomes. In: Lasic D, ed. Stealth liposomes. Boca Raton, FL: CRC 1995: 173-85
36. Mauk MR, Gamble RC. Stability of lipid vesicles in tissues of the mouse: a gamma-ray perturbed angular correlation study. Proc Natl Acad Sci USA 1979; 76: 765-9
37. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-6